Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(16):1162; doi:10.1093/jnci/djj323
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vakaet, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vakaet, L.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

CORRESPONDENCE

Re: Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

Luc Vakaet

Correspondence to: Luc Vakaet, MD, PhD, UZ Gent, Radiotherapie, De Pintelaan 185, Gent 9000, Belgium (e-mail: luc.vakaet@ugent.be).

The first 10% of the full text of this article appears below.

I read with great interest the updated findings of the NCIC CTG MA.17 trial (1) and want to compliment the authors for continuing to report on this . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE
Dongsheng Tu, Joseph L. Pater, James N. Ingle, and Paul E. Goss
J Natl Cancer Inst 2006 98: 1162-1163. [Extract] [Full Text] [PDF]